A transpa­cif­ic biotech start­up com­bines Asian in­vestors and some se­ri­ous­ly trendy sci­ence out of MIT

Syn­thet­ic bi­ol­o­gist Tim­o­thy Lu has been do­ing some mind blow­ing sci­en­tif­ic work at MIT. A few months ago he and some of his col­leagues wrote up their work de­sign­ing and cre­at­ing mam­malian ge­net­ic cir­cuits that could be used to spawn, say, a whole new breed of T cells that could be en­gi­neered to go on the at­tack against can­cer cells — with built-in trig­gers to a set of bio­mark­ers.

Jef­frey Lu

This fas­ci­na­tion with syn­thet­ic bi­ol­o­gy — along with some close ties to the lead­ers in this emerg­ing field — has spurred Lu to part­ner with his broth­er Jef­frey on cre­at­ing a transpa­cif­ic biotech dubbed En­gine Bio­sciences that plans to in­te­grate ar­ti­fi­cial in­tel­li­gence and ma­chine learn­ing with hands-on lab work in drug de­vel­op­ment to cre­ate a whole new kind of drug de­vel­op­ment plat­form, one they say can test a dizzy­ing ar­ray of ge­net­ic in­ter­ac­tions in par­al­lel in search of those nee­dles in the da­ta in­tense haystack that can point to mul­ti­ple drug pro­grams.

It is the buzzi­est of all biotech types fo­cused on some of the trendi­est dis­cov­ery work now dom­i­nat­ing the dis­cus­sion in bio­phar­ma’s pre­clin­i­cal cir­cles. That’s pret­ty good for a com­pa­ny that cur­rent­ly has 6 full-time em­ploy­ees. But there’s al­so more here than lab projects and sci­ence pa­pers.

To­day En­gine is tak­ing the wraps off a $10 mil­lion seed round com­ing from a col­lec­tion of some very se­ri­ous in­vestors fund­ing the cur­rent burst of biotech ac­tiv­i­ty in places like Shang­hai and Sin­ga­pore.

Hu Li

The mon­ey is com­ing from a set of in­vestors with deep roots in Asia: DHVC (AI spe­cial­ists at Dan­hua Cap­i­tal) and 6 Di­men­sions Cap­i­tal (re­cent­ly formed through the merg­er of Front­line Bioven­tures and WuXi Health­care Ven­tures in May 2017). WuXi AppTec, Sin­ga­pore’s ED­BI, Temasek sub Pavil­ion Cap­i­tal, Baidu Ven­tures, WI Harp­er, and Nest.Bio Ven­tures al­so got in­volved.

The work at En­gine will be done in the Bay Area and Sin­ga­pore, where Tim­o­thy Lu has a lab. And it will in­volve a slate of some big names in the field: Mayo Clin­ic as­sis­tant pro­fes­sor Hu Li, Uni­ver­si­ty of Cal­i­for­nia San Diego as­sis­tant pro­fes­sor Prashant Mali, and co-chair of the sci­en­tif­ic ad­vi­so­ry board and MIT pro­fes­sor Jim Collins.

The drug de­vel­op­ment cy­cle as we know it now is chal­lenged by com­plex bi­ol­o­gy and a one-by-one ap­proach that in­vites slow de­vel­op­ment time­lines and ex­tra­or­di­nar­i­ly high fail­ure rates, says CEO and co-founder Jef­frey Lu. Fig­ur­ing out every­thing from tar­get dis­cov­ery to strat­i­fi­ca­tion of pa­tient pop­u­la­tions re­quires a com­plex as­sess­ment of all those fac­tors.

Their plat­form looks to an­swer those ques­tions in a fast and ef­fi­cient man­ner.

“That’s the mis­sion of the com­pa­ny,” says Jef­frey Lu.

Jim Collins

That cov­ers a vast amount of pos­si­bil­i­ties, of course, so En­gine is nar­row­ing it down to on­col­o­gy, with work un­der­way on liv­er can­cer and ovar­i­an can­cer, and con­struc­tion in process on a neu­rode­gen­er­a­tive plat­form. There’s al­so a project for skin ag­ing, work­ing with a skin care group. And there are plans to part­ner ear­ly and of­ten.

“We thought it was im­por­tant to have a wet lab bi­ol­o­gy da­ta gen­er­a­tion tool that gen­er­ates our own pro­pri­etary dataset so we can train al­go­rithms to get bet­ter and bet­ter, im­prov­ing the pre­dic­tive ca­pa­bil­i­ties of our in sil­i­co meth­ods,” says Jef­frey Lu. And now that the seed round is in place, he’ll be dou­bling or tripling the small staff by the end of this year to start turn­ing their plat­form dreams in­to re­al­i­ty.

The mon­ey, he says, should last two years.


Im­age: Tim­o­thy Lu. MIT Cam­paign for a Bet­ter World

Da­ta Lit­er­a­cy: The Foun­da­tion for Mod­ern Tri­al Ex­e­cu­tion

In 2016, the International Council for Harmonisation (ICH) updated their “Guidelines for Good Clinical Practice.” One key shift was a mandate to implement a risk-based quality management system throughout all stages of a clinical trial, and to take a systematic, prioritized, risk-based approach to clinical trial monitoring—on-site monitoring, remote monitoring, or any combination thereof.

Pfiz­er's big block­buster Xel­janz flunks its post-mar­ket­ing safe­ty study, re­new­ing harsh ques­tions for JAK class

When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study.

That study has since become a consistent headache for Pfizer and their blockbuster molecule. Last year, Pfizer dropped the entire high dose cohort after an independent monitoring board found more patients died in that group than in the low dose arm or a control arm of patients who received one of two TNF inhibitors, Enbrel or Humira.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 99,000+ biopharma pros reading Endpoints daily — and it's free.

Top gene ther­a­py deals, M&A pacts in 2020 high­light an­oth­er big year in one of the hottest fields in bio­phar­ma

Chris Dokomajilar at DealForma has been crunching the numbers on gene therapy deals over the last 2 years and came away with a few key observations.

Both the upfront cash and deal totals last year backed off a bit from the record high hit in 2019, but the totals are still running well ahead of anything we’ve seen in the years prior to 2019/2020.
2020 R&D partnerships came in at 23 deals, with $1.1 billion in disclosed upfront cash and equity and more than $8.5 billion in total deal value. Looking at 2019-2020 M&A, Dokomajilar found: 9 Acquisitions, with over $11.1 billion in disclosed upfront cash and equity and more than $13.4 billion in total M&A value.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 99,000+ biopharma pros reading Endpoints daily — and it's free.

Bob Nelsen (Michael Kovac/Getty Images)

ARCH an­nounces largest fund yet, rais­ing $1.85B to back men­tal health, cell and gene edit­ing ap­proach­es

Nearly a year ago, as the pandemic encroached and the stock market cratered, Flagship and ARCH Venture announced three mega-funds worth a combined $2.6 billion. They wanted, ARCH’s Bob Nelsen said, to restore confidence “that there was money out there and a lot of it” to invest in biotech.

Since then, the stock market has returned — almost frighteningly so — and Nelsen has kept raising and spending cash. On Thursday, he announced a new fund, worth $1.85 billion. It’s the largest pot yet for a VC famous for its deep pockets.

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

After coming under fire for manufacturing delays last week, AstraZeneca’s feud with the European Union has spilled into the open.

The bloc accused the pharma giant on Wednesday of pulling out of a meeting to discuss cuts to its vaccine supplies, the AP reported. AstraZeneca denied the reports, saying it still planned on attending the discussion.

Early Wednesday, an EU Commission spokeswoman said that “the representative of AstraZeneca had announced this morning, had informed us this morning that their participation is not confirmed, is not happening.” But an AstraZeneca spokesperson later called the reports “not accurate.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 99,000+ biopharma pros reading Endpoints daily — and it's free.

Janet Woodcock (AP Images)

Ad­vo­ca­cy groups don't want Janet Wood­cock to head the FDA, blast­ing ‘reg­u­la­to­ry fail­ures’ in opi­oid cri­sis

It turns out the controversies around Janet Woodcock’s regulatory legacy weren’t limited to Sarepta’s eteplirsen.

A coalition of advocacy groups dedicated to the opioid crisis urged Norris Cochran and Xavier Becerra — the acting and designated HHS secretary, respectively — to keep her reign as interim FDA chief a “very short transition.” During her lengthy tenure as CDER, they add, Woodcock presided over “one of the worst regulatory agency failures in U.S. history.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 99,000+ biopharma pros reading Endpoints daily — and it's free.

Dean Li kicks off Mer­ck­'s post-Roger Perl­mut­ter era by team­ing with Arti­va and its off-the-shelf CAR-NK tech

Even though Dean Li has now officially taken over for Roger Perlmutter as R&D chief, Merck’s appetite for dealmaking continues to be ravenous.

Li struck his first big deal at the helm Thursday morning, hammering out a collaboration with Artiva Biotherapeutics that could earn the biotech nearly $1.9 billion when all is said and done. It’s a quick rise and validation for Artiva, which just last June launched with a $78 million Series A.

Take­da earns win for its TKI in­hibitor in tiny lung can­cer group — but GI side ef­fects could be an ear­ly red flag

Japanese drugmaker Takeda has made a big push in recent years to build a hand in oncology, particularly in the next-gen cancer space. One of those candidates, tyrosine kinase inhibitor (TKI) mobocertinib, recently earned the FDA’s interest in a small section of untreated lung cancer patients, but will severe GI side effects be a roadblock?

Takeda’s oral mobocertinib posted clinically significant objective response rates in a Phase I/II adaptive trial drugging metastatic non-small cell lung cancer patients with EGFR exon 20 gene mutations who had previously undergone platinum-based chemotherapy, according to data presented Thursday at the virtual World Conference on Lung Cancer.

Covid-19 roundup: Con­tro­ver­sy around colchicine per­co­lates af­ter study fail­ure; As­traZeneca's meet­ing with EU was 'con­struc­tive,' but did­n't solve much

A group of researchers at the Montreal Heart Institute has spelled out what they had called positive results suggesting that colchicine, an inexpensive oral anti-inflammatory drug commonly used to treat gout, could prevent Covid-19 complications in newly diagnosed patients.

The study failed its primary endpoint. But the latest scientific debate around treatments for the coronavirus is just beginning to brew.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 99,000+ biopharma pros reading Endpoints daily — and it's free.